Compare CRBU & HYPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRBU | HYPR |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United States |
| Employees | N/A | 102 |
| Industry | Medicinal Chemicals and Botanical Products | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.6M | 94.7M |
| IPO Year | 2021 | 2021 |
| Metric | CRBU | HYPR |
|---|---|---|
| Price | $1.57 | $0.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $10.75 | $1.59 |
| AVG Volume (30 Days) | ★ 2.4M | 1.7M |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.64 | ★ 23.21 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $13,563,000.00 |
| Revenue This Year | $1.63 | $50.75 |
| Revenue Next Year | $10.93 | $29.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5.22 |
| 52 Week Low | $1.38 | $0.85 |
| 52 Week High | $3.53 | $2.22 |
| Indicator | CRBU | HYPR |
|---|---|---|
| Relative Strength Index (RSI) | 35.14 | 32.72 |
| Support Level | $1.39 | $0.88 |
| Resistance Level | $1.73 | $1.19 |
| Average True Range (ATR) | 0.11 | 0.07 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 0.94 | 16.26 |
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales, which consist of sales from subscriptions of bundled devices, maintenance, and software. The company is in the health technology business with a mission to revolutionize patient care globally through accessible, affordable, clinically relevant artificial intelligence (AI)-powered portable ultra-low-field (ULF) magnetic resonance (MR) brain imaging. The Company operates in one business segment, which includes all activities related to production, supply, service, and commercialization of the Swoop system.